Group III mGlu receptor agonist, ACPT-I, exerts potential neuroprotective effects in vitro and in vivo

Neurotoxicity Research

Volumn 26, Issue 1, 2014, Pages 99-113

  Domin, Helena ^a   Gołembiowska, Krystyna ^a   Jantas, Danuta ^a   Kamińska, Katarzyna ^a   Zięba, Barbara ^a   Śmiałowska, Maria ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

ACPT I; Excitotoxicity; Glutamate release; Group III mGlu receptors; Kainic acid; Neuroprotection

Indexed keywords

1 AMINOCYCLOPENTANE 1,2,4 TRICARBOXYLIC ACID; CASPASE 3; GLUTAMIC ACID; KAINIC ACID; METABOTROPIC RECEPTOR AGONIST; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG; 1-AMINOCYCLOPENTANE-1,3,4-TRICARBOXYLIC ACID; AMINO ACID RECEPTOR STIMULATING AGENT; CYCLOPENTANE DERIVATIVE; METABOTROPIC RECEPTOR; TRICARBOXYLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DOSE COMPARISON; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; EXCITOTOXICITY; HIPPOCAMPAL CA1 REGION; IN VITRO STUDY; IN VIVO STUDY; MALE; NERVE CELL CULTURE; NERVE CELL LESION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL TRACT; RAT; STEREOLOGY; AGONISTS; ANIMAL; BRAIN CORTEX; CELL CULTURE; DRUG EFFECTS; EXTRACELLULAR SPACE; HIPPOCAMPUS; METABOLISM; MOUSE; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TOXICITY; WISTAR RAT;

RATTUS;

ANIMALS; CELLS, CULTURED; CEREBRAL CORTEX; CYCLOPENTANES; EXCITATORY AMINO ACID AGONISTS; EXTRACELLULAR SPACE; GLUTAMIC ACID; HIPPOCAMPUS; KAINIC ACID; MALE; MICE; NEURONS; NEUROPROTECTIVE AGENTS; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE; TRICARBOXYLIC ACIDS;

EID: 84903784031     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-013-9455-7     Document Type: Article

References (84)

1. Acher FC, Tellier FJ, Azerad R, Brabet IN, Fagni L, Pin JP (1997) Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes. J Med Chem 40:3119-3129 (Pubitemid 27391544)
2. Arundine M, Tymianski M (2003) Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 34:325-337 (Pubitemid 37021228)
3. Baskys A, Malenka RC (1991) Agonists at metabotropic glutamate receptors presynaptically inhibit EPSCs in neonatal rat hippocampus. J Physiol 444:687-701
4. Bradley SR, Levey AI, Hersch SM, Conn PJ (1996) Immunocytochemical localization of group III metabotropic glutamate receptors in the hippocampus with subtype-specific antibodies. J Neurosci 16:2044-2056 (Pubitemid 26144017)
5. Brewer GJ (1995) Serum-free B27/neurobasal medium supports differentiated growth of neurones from the striatum, substantia nigra, septum, cerebral cortex, cerebellum and dentate gyrus. J Neurosci Res 42:674-683
6. Bruno V, Battaglia G, Copani A, Giffard RG, Raciti G, Raffaele R, Shinozaki H, Nicoletti F (1995) Activation of class II or III metabotropic glutamate receptors protects cultured cortical neurons against excitotoxic degeneration. Eur J Neurosci 7:1906-1913
7. Bruno V, Copani A, Bonanno L, Knoepfel T, Kuhn R, Roberts PJ, Nicoletti F (1996) Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures. Eur J Pharmacol 310:61-66 (Pubitemid 26284257)
8. Bruno V, Battaglia G, Ksiazek I, van der Putten H, Catania MV, Giuffrida R, Lukic S, Leonhardt T, Inderbitzin W, Gasparini F, Kuhn R, Hampson DR, Nicoletti F, Flor PJ (2000) Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death. J Neurosci 20:6413-6420
9. Byrnes KR, Loane DJ, Faden AI (2009) Metabotropic glutamate receptors as targets for multipotential treatment of neurological disorders. Neurotherapeutics 6:94-107
10. Cartmell J, Schoepp DD (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75:889-907 (Pubitemid 30660476)
11. Chapman AG, Nanan K, Yip P, Meldrum BS (1999) Anticonvulsant activity of a metabotropic glutamate receptor 8 preferential agonist, (R,S)-4- phosphonophenylglycine. Eur J Pharmacol 383:23-27 (Pubitemid 29509818)
12. Chapman AG, Talebi A, Yip PK, Meldrum BS (2001) Anticonvulsant activity of a mGlu(4alpha) receptor selective agonist, (1S,3R,4S)-1-aminocyclopentane-1, 2,4-tricarboxylic acid. Eur J Pharmacol 424:107-113 (Pubitemid 32718614)
13. Chittajallu R, Vignes M, Dev KK, Barnes JM, Collingridge GL, Henley JM (1996) Regulation of glutamate release by presynaptic kainate receptors in the hippocampus. Nature 379:78-81 (Pubitemid 26008139)
14. Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237 (Pubitemid 27238875)
15. Coyle JT (1983) Neurotoxic action of kainic acid. J Neurochem 41:1-11
16. Danysz W, Parsons CG (1998) Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 50:597-664 (Pubitemid 29028813)
17. De Colle C, Bessis AS, Bockaert J, Acher F, Pin JP (2000) Pharmacological characterization of the rat metabotropic glutamate receptor type 8a revealed strong similarities and slight differences with the type 4a receptor. Eur J Pharmacol 394:17-26 (Pubitemid 30193283)
18. De Sarro G, Chimirri A, Meldrum BS (2002) Group III mGlu receptor agonists potentiate the anticonvulsant effect of AMPA and NMDA receptor block. Eur J Pharmacol 451:55-61 (Pubitemid 35246365)
19. Domin H, Kajta M, Smiałowska M (2006) Neuroprotective effects of MTEP, a selective mGluR5 antagonists and neuropeptide Y on the kainate-induced toxicity in primary neuronal cultures. Pharmacol Rep 58:846-858 (Pubitemid 46117736)
20. Domin H, Ziȩba B, Gołembiowska K, Kowalska M, Dziubina A, Śmiałowska M (2010) Neuroprotective potential of mGluR5 antagonist MTEP: effects on kainate-induced excitotoxicity in the rat hippocampus. Pharmacol Rep 62:1051-1061
21. Evans DI, Jones RS, Woodhall G (2000) Activation of presynaptic group III metabotropic receptors enhances glutamate release in rat entorhinal cortex. J Neurophysiol 83:2519-2525 (Pubitemid 30321446)
22. Faden AI, Ivanova SA, Yakovlev AG, Mukhin AG (1997) Neuroprotective effects of group III mGluR in traumatic neuronal injury. J Neurotrauma 14:885-895 (Pubitemid 28087514)
23. Ferkany JW, Coyle JT (1983) Kainic acid selectively stimulates the release of endogenous excitatory acidic amino acids. J Pharmacol Exp Ther 225:399-406 (Pubitemid 13091231)
24. Ferkany JW, Zaczek R, Coyle JT (1982) Kainic acid stimulates excitatory amino acid neurotransmitter release at presynaptic receptors. Nature 298:757-759 (Pubitemid 12041373)
25. Flor PJ, Van Der Putten H, Rüegg D, Lukic S, Leonhardt T, Bence M, Sansig G, Knöpfel T, Kuhn R (1997) A novel splice variant of a metabotropic glutamate receptor, human mGluR7b. Neuropharmacology 36:153-159 (Pubitemid 27149503)
26. Folbergrová J, Haugvicová R, Mares P (2003) Seizures induced by homocysteic acid in immature rats are prevented by group III metabotropic glutamate receptor agonist (R,S)-4-phosphonophenylglycine. Exp Neurol 180:46-54 (Pubitemid 36379006)
27. Folbergrová J, Druga R, Haugvicová R, Mares P, Otáhal J (2008) Anticonvulsant and neuroprotective effect of (S)-3,4-dicarboxyphenylglycine against seizures induced in immature rats by homocysteic acid. Neuropharmacology 54:665-675
28. Forsythe ID, Clements JD (1990) Presynaptic glutamate receptors depress excitatory monosynaptic transmission between mouse hippocampal neurones. J Physiol 429:1-16 (Pubitemid 20327534)
29. Gasparini F, Bruno V, Battaglia G, Lukic S, Leonhardt T, Inderbitzin W, Laurie D, Sommer B, Varney MA, Hess SD, Johnson EC, Kuhn R, Urwyler S, Sauer D, Portet C, Schmutz M, Nicoletti F, Flor PJ (1999) (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J Pharmacol Exp Ther 289:1678-1687 (Pubitemid 29246706)
30. Gereau RW IV, Conn PJ (1995) Multiple presynaptic metabotropic glutamate receptors modulate excitatory and inhibitory synaptic transmission in hippocampal area CA1. J Neurosci 15:6879-6889
31. Gołembiowska K, Dziubina A (2004a) Effect of the adenosine A2A receptor antagonist 8-(3-chlorostyryl)caffeine on L-DOPA biotransformation in rat striatum. Brain Res 998:208-217 (Pubitemid 38125062)
32. Gołembiowska K, Dziubina A (2004b) Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following L-DOPA administration in intact and dopamine-denervated rats. Neuropharmacology 47:414-426 (Pubitemid 38953233)
33. Goudet C, Chapuy E, Alloui A, Acher F, Pin JP, Eschalier A (2008) Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain. Pain 137:112-124 (Pubitemid 351802243)
34. Gundersen HJ, Jensen EB (1987) The efficiency of systematic sampling in stereology and its prediction. J Microsc 147:229-263
35. Iacovelli L, Bruno V, Salvatore L, Melchiorri D, Gradini R, Caricasole A, Barletta E, De Blasi A, Nicoletti F (2002) Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways. J Neurochem 82:216-223 (Pubitemid 34774613)
36. Ikonomidou C, Turski L (2002) Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 1:383-386 (Pubitemid 37159164)
37. Jantas D, Lorenc-Koci E, Kubera M, Lason W (2011) Neuroprotective effects of MAPK/ERK1/2 and calpain inhibitors on lactacystin-induced cell damage in primary cortical neurons. Neurotoxicology 32:845-856
38. Jantas D, Krawczyk S, Lason W (2013) The predominant protective effect of tianeptine over other antidepressants in models of neuronal apoptosis: the effect blocked by inhibitors of MAPK/ERK1/2 and PI3-K/Akt pathways. Neurotox Res 9. doi:10.1007/s12640-013-9430-3
39. Jin X, Daw NW (1998) The group III metabotropic glutamate receptor agonist, l-AP4, reduces EPSPs in some layers of rat visual cortex. Brain Res 797:218-224 (Pubitemid 28332734)
40. Kajta M, Lasoń W, Kupiec T (2004) Effects of estrone on N-methyl-D-aspartic acid- and staurosporine-induced changes in caspase-3-like protease activity and lactate dehydrogenase-release: time and tissue-dependent effects in neuronal cultures. Neuroscience 123:515-526 (Pubitemid 38032927)
41. Kajta M, Domin H, Grynkiewicz G, Lason W (2007) Genistein inhibits glutamate-induced apoptotic processes in primary neuronal cell cultures: an involvement of aryl hydrocarbon receptor and estrogen receptor/glycogen synthase kinase-3beta intracellular signaling pathway. Neuroscience 145:592-604 (Pubitemid 46341646)
42. Kłak K, Pałucha A, Brański P, Sowa M, Pilc A (2007) Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats. Amino Acids 32:169-172 (Pubitemid 46198739)
43. Knecht R, Chang JY (1986) Liquid chromatographic determination of amino acids after gas-phase hydrolysis and derivatization with (dimethylamino) azobenzenesulfonyl chloride. Anal Chem 58:2375-2379
44. Koerner JF, Cotman CW (1981) Micromolar L-2-amino-4-phosphonobutyric acid selectively inhibits perforant path synapses from lateral entorhinal cortex. Brain Res 216:192-198 (Pubitemid 11121177)
45. Konieczny J, Wardas J, Kuter K, Pilc A, Ossowska K (2007) The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1- aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats. Neuroscience 145:611-620 (Pubitemid 46341652)
46. Lafon-Cazal M, Fagni L, Guiraud MJ, Mary S, Lerner-Natoli M, Pin JP, Shigemoto R, Bockaert J (1999) mGluR7-like metabotropic glutamate receptors inhibit NMDA-mediated excitotoxicity in cultured mouse cerebellar granule neurons. Eur J Neurosci 11:663-672 (Pubitemid 29050468)
47. Lea PM 4th, Faden AI (2003) Modulation of metabotropic glutamate receptors as potential treatment for acute and chronic neurodegenerative disorders. Drug News Perspect 16:513-522
48. Lopez S, Turle-Lorenzo N, Acher F, De Leonibus E, Mele A, Amalric M (2007) Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. J Neurosci 27:6701-6711 (Pubitemid 46983444)
49. Lopez S, Turle-Lorenzo N, Johnston TH, Brotchie JM, Schann S, Neuville P, Amalric M (2008) Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. Neuropharmacology 55:483-490
50. Lopez S, Jouve L, Turle-Lorenzo N, Kerkerian-Legoff L, Salin P, Amalric M (2012) Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivity. Neurobiol Dis 46:69-77
51. Maiese K, Chong ZZ, Li F (2005) Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors. Curr Neurovasc Res 2:425-446 (Pubitemid 41789608)
52. Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W, Stoehr N, Stein T, Gasparini F, Vranesic I, Kuhn R, Nicoletti F, Flor PJ (2003) (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology 45:895-906 (Pubitemid 37297915)
53. Malva JO, Carvalho AP, Carvalho CM (1998) Kainate receptors in hippocampal CA3 subregion: evidence for a role in regulating neurotransmitter release. Neurochem Int 32:1-6 (Pubitemid 28020230)
54. Mazzone GL, Nistri A (2011) Delayed neuroprotection by riluzole against excitotoxic damage evoked by kainate on rat organotypic spinal cord cultures. Neuroscience 190:318-327
55. Mazzone GL, Margaryan G, Kuzhandaivel A, Nasrabady SE, Mladinic M, Nistri A (2010) Kainate-induced delayed onset of excitotoxicity with functional loss unrelated to the extent of neuronal damage in the in vitro spinal cord. Neuroscience 168:451-462
56. Moldrich RX, Beart PM, Jane DE, Chapman AG, Meldrum BS (2001) Anticonvulsant activity of 3,4-dicarboxyphenylglycines in DBA/2 mice. Neuropharmacology 40:732-735 (Pubitemid 32323997)
57. Moldrich RX, Chapman AG, De Sarro G, Meldrum BS (2003) Glutamate metabotropic receptors as targets for drug therapy in epilepsy. Eur J Pharmacol 476:3-16 (Pubitemid 37321352)
58. Muir KW, Lees KR (1995) Clinical experience with excitatory amino acid antagonist drugs. Stroke 26:503-513
59. Nadler JV, Perry BW, Cotman CW (1978) Intraventricular kainic acid preferentially destroys hippocampal pyramidal cells. Nature 271:676-677 (Pubitemid 8278952)
60. Nakajima Y, Iwakabe H, Akazawa C, Nawa H, Shigemoto R, Mizuno N, Nakanishi S (1993) Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate. J Biol Chem 268:11868-11873 (Pubitemid 23168143)
61. Nicoletti F, Bruno V, Copani A, Casabona G, Knöpfel T (1996) Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci 19:267-271 (Pubitemid 26000672)
62. Okamoto N, Hori S, Akazawa C, Hayashi Y, Shigemoto R, Mizuno N, Nakanishi S (1994) Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction. J Biol Chem 269:1231-1236 (Pubitemid 24032512)
63. Pałucha A, Tatarczyńska E, Brański P, Szewczyk B, Wierońska JM, Kłak K, Chojnacka-Wójcik E, Nowak G, Pilc A (2004) Group III mGlu receptor agonists produce anxiolytic- and antidepressantlike effects after central administration in rats. Neuropharmacology 46:151-159 (Pubitemid 37532823)
64. Pałucha-Poniewiera A, Kłodzińska A, Stachowicz K, Tokarski K, Hess G, Schann S, Frauli M, Neuville P, Pilc A (2008) Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents. Neuropharmacology 55:517-524
65. Panatier A, Poulain DA, Oliet SH (2004) Regulation of transmitter release by high-affinity group III mGluRs in the supraoptic nucleus of the rat hypothalamus. Neuropharmacology 47:333-341 (Pubitemid 38953224)
66. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic Press, San Diego
67. Pin JP, Duvoisin R (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34:1-26
68. Pizzi M, Benarese M, Boroni F, Goffi F, Valerio A, Spano PF (2000) Neuroprotection by metabotropic glutamate receptor agonists on kainate-induced degeneration of motor neurons in spinal cord slices from adult rat. Neuropharmacology 39:903-910 (Pubitemid 30103694)
69. Sakahira H, Enari M, Nagata S (1998) Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 391:96-99 (Pubitemid 28079223)
70. Schann S, Menet C, Arvault P, Mercier G, Frauli M, Mayer S, Hubert N, Triballeau N, Bertrand HO, Acher F, Neuville P (2006) Design and synthesis of APTCs (aminopyrrolidinetricarboxylic acids): identification of a new group III metabotropic glutamate receptor selective agonist. Bioorg Med Chem Lett 16:4856-4860 (Pubitemid 44175855)
71. Schoepp DD (2001) Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 299:12-20
72. Shigemoto R, Kinoshita A, Wada E, Nomura S, Ohishi H, Takada M, Flor PJ, Neki A, Abe T, Nakanishi S, Mizuno N (1997) Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci 17:7503-7522 (Pubitemid 27413281)
73. Śmiałowska M, Wierońska JM, Szewczyk B (2003) Neuroprotective effect of NPY on kainate neurotoxicity in the hippocampus. Pol J Pharmacol 55:979-986 (Pubitemid 38128933)
74. Śmiałowska M, Domin H, Zieba B, Koźniewska E, Michalik R, Piotrowski P, Kajta M (2009) Neuroprotective effects of neuropeptide Y-Y2 and Y5 receptor agonists in vitro and in vivo. Neuropeptides 43:235-249
75. Śmiałowska M, Gołembiowska K, Kajta M, Ziȩba B, Dziubina A, Domin H (2012) Selective mGluR1 antagonist EMQMCM inhibits the kainate-induced excitotoxicity in primary neuronal cultures and in the rat hippocampus. Neurotox Res 21:379-392
76. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R (2003) Insight into the function of group I and group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14:257-277 (Pubitemid 36900596)
77. Stachowicz K, Chojnacka-Wójcik E, Kłak K, Pilc A (2006) Anxiolytic-like effects of group III mGlu receptor ligands in the hippocampus involve GABAA signaling. Pharmacol Rep 58:820-826 (Pubitemid 46117733)
78. Stachowicz K, Kłodzińska A, Palucha-Poniewiera A, Schann S, Neuville P, Pilc A (2009) The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems. Neuropharmacology 57:227-234
79. Tatarczyńska E, Pałucha A, Szewczyk B, Chojnacka- Wójcik E, Wierońska J, Pilc A (2002) Anxiolytic- and antidepressant-like effects of group III metabotropic glutamate agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in rats. Pol J Pharmacol 54:707-710 (Pubitemid 36124524)
80. Toms NJ, Jane DE, Kemp MC, Bedingfield JS, Roberts PJ (1996) The effects of (RS)-alpha-cyclopropyl-4-phosphonophenylglycine ((RS)-CPPG), a potent and selective metabotropic glutamate receptor antagonist. Br J Pharmacol 119:851-854 (Pubitemid 26366477)
81. Vernon AC, Croucher MJ, Dexter DT (2008) Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model. NeuroReport 19:475-478 (Pubitemid 351301609)
82. Wang Q, Yu S, Simonyi A, Sun GY, Sun AY (2005) Kainic acid-mediated excitotoxicity as a model for neurodegeneration. Mol Neurobiol 31:3-16 (Pubitemid 41271190)
83. Wang WY, Wang H, Luo Y, Jia LJ, Zhao JN, Zhang HH, Ma ZW, Xue QS, Yu BW (2012) The effects of metabotropic glutamate receptor 7 allosteric agonist N,N′-dibenzhydrylethane-1,2-diamine dihydrochloride on developmental sevoflurane neurotoxicity: role of extracellular signal-regulated kinase 1 and 2 mitogen-activated protein kinase signaling pathway. Neuroscience 205:167-177
84. Zhao L, Qian ZM, Zhang C, Wing HY, Du F, Ya K (2008) Amyloid beta-peptide 31-35-induced neuronal apoptosis is mediated by caspase-dependent pathways via cAMP-dependent protein kinase A activation. Aging Cell 7:47-57